Extended Release Felodipine in Essential Hypertension

Fariello, R; Luciano, Enrico Boni Corda; Cantalamessa, A; Zaninelli, Augusto; Pollavini, G.; Alicandri, C; Muiesan, G

doi:10.1093/ajh/4.1.27

Cited by 25 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Felodipine is a dihydropyridine calcium antagonist, with an elimination half‐life of 24 hours (mean value in middle‐aged patients) 7 . Studies in hypertensive patients, several of which have included ambulatory blood pressure monitoring, have shown that the antihypertensive effect of felodipine extended‐release (ER) tablets given once daily is maintained for 24 hours 8 , 9 . The usual maintenance dose is 5–10 mg per day.…”

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

“…Reflex increases in heart rate commonly occur after initial doses of dihydropyridine calcium antagonists. With felodipine extended‐release tablets 5 mg the increase in heart rate with the first dose is modest, being about 2–6 beats/min, with the heart rate returning to normal during long‐term treatment 9 , 13 , 14 . Extensive clinical data are available on felodipine in hypertension, where it has been shown to be effective when used as monotherapy or in combination with other antihypertensives 15 …”

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

“…7 Studies in hypertensive patients, several of which have included ambulatory blood pressure monitoring, have shown that the antihypertensive effect offelodipine extended-release (ER) tablets given once daily is _maintained for 24 hours. 8 • 9 The usual maintenance dose is 5-10 mg per day. Felodipine is highly vascular selective, which means that profound arteriolar dilatation can be obtained at doses that do not affect cardiac contractility or conduction.…”

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

“…Herlitz et al investigated the long-tenn effects of felodipine in patients with previously refractory hypertension and renal impainnent. 48 .4 9 The study included 14 patients, 8 with moderately impaired but stable renal function and 6 with severe and progressive impainnent of renal function. Patients' blood pressures were uncontrolled despite 3-4 drugs, which in 11 patients included an ACE inhibitor.…”

Section: Glomerular Injurymentioning

confidence: 99%

See 3 more Smart Citations

Structural Changes in Hypertension, the Potential for Their Prevention, Arrest and Reversal: A Focus on Felodipine

Purcell¹,

Coats²

1994

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARY Hypertension is accompanied by a series of structural adaptations and pathological alterations in the heart and vessels. These include hypertrophy of the left ventricle and walls of resistance vessels, degeneration of elastic components in the walls of large arteries, atherosclerosis and glomerulosclerosis. In order to improve prognosis it is important that the antihypertensive drugs used can prevent or regress these processes, and this review focuses on the experience with the vascular selective calcium antagonist felodipine. Clinical studies show that antihypertensive treatment with felodipine promotes regression of left ventricular hypertrophy, increases compliance of large arteries, and has favourable effects on renal function. In addition, experimental data have shown that felodipine inhibits atherosclerotic plaque development. As structural cardiovascular changes appear early in hypertension, intervention with antihypertensive therapy is better initiated sooner than later. Vascular selective calcium antagonists, such as felodipine, appear effective in reducing blood pressure and in ameliorating hypertension‐induced structural changes.

show abstract

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

Section: Clinical Profile Of Felodipinementioning

confidence: 99%

Section: Glomerular Injurymentioning

confidence: 99%

See 2 more Smart Citations

Structural Changes in Hypertension, the Potential for Their Prevention, Arrest and Reversal: A Focus on Felodipine

Purcell¹,

Coats²

1994

Int J Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Un estudio realizado en Italia, con un protocolo de ejercicio semejante al del experimento descrito anteriormente, demostró beneficios sólo en 4 de 7 hipertensos leves a moderados, a pesar de que en todos mejoraron la capacidad física, la entrega de oxígeno y la capacidad de trabajo (26).…”

Section: Reduccion De Pesounclassified

Tratamiento no farmacológico de la hipertensión arterial

Villegas

1992

Iatreia

View full text Add to dashboard Cite

El manejo no farmacológico se recomienda como terapia inicial en todo paciente con hipertensión arterial pero ha sido ampliamente desplazado por el tratamiento farmacológico. Los avances recientes permiten concluir que la reducción de peso, la restricción moderada de sal y el ejercicio son las modalidades que mayores beneficios producen en el hipertenso. Los resultados del manejo del estrés, de la modificación de la dieta y de los suplementos de calcio, magnesio, potasio, vitamina D y ácido gama amino Iinolénico son más controvertidos.

show abstract

Do the Differences Between Calcium Antagonists Matter When Treating Hypertension?

Morgan

Anderson

1993

Calcium Antagonists

View full text Add to dashboard Cite

Extended Release Felodipine in Essential Hypertension

Cited by 25 publications

References 0 publications

Structural Changes in Hypertension, the Potential for Their Prevention, Arrest and Reversal: A Focus on Felodipine

Structural Changes in Hypertension, the Potential for Their Prevention, Arrest and Reversal: A Focus on Felodipine

Tratamiento no farmacológico de la hipertensión arterial

Do the Differences Between Calcium Antagonists Matter When Treating Hypertension?

Contact Info

Product

Resources

About